ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results
Emily K. Slotkin(Memorial Sloan Kettering Cancer Center), William D. Tap(Memorial Sloan Kettering Cancer Center), Michael D. Kinnaman(Regeneron (United States)), Caroline M. Robb(Memorial Sloan Kettering Cancer Center), Gerald Behr, Viswatej Avutu(Memorial Sloan Kettering Cancer Center), Neeta Pandit‐Taskar(Memorial Sloan Kettering Cancer Center), Paul A. Meyers(Memorial Sloan Kettering Cancer Center), Ping Chi(Memorial Sloan Kettering Cancer Center), Sagarika Pachhal(Memorial Sloan Kettering Cancer Center), Audrey Mauguen(Memorial Sloan Kettering Cancer Center), Sinchun Hwang(Memorial Sloan Kettering Cancer Center), Damon R. Reed(Memorial Sloan Kettering Cancer Center), Romel Somwar(Memorial Sloan Kettering Cancer Center), Mrinal M. Gounder(Memorial Sloan Kettering Cancer Center), Tara J. O’Donohue, Mark A. Dickson(Memorial Sloan Kettering Cancer Center), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Benjamin A. Nacev(University of Pittsburgh), Evan Rosenbaum(Memorial Sloan Kettering Cancer Center), Alex Kentsis(Memorial Sloan Kettering Cancer Center), Andrew L. Kung(Memorial Sloan Kettering Cancer Center), Filemon S. Dela Cruz, Ciara M. Kelly(Memorial Sloan Kettering Cancer Center), Leonard H. Wexler(Memorial Sloan Kettering Cancer Center), Michael V. Ortiz(Memorial Sloan Kettering Cancer Center), Julia Glade Bender(Columbia University Irving Medical Center), Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), Mary Lou Keohan(Memorial Sloan Kettering Cancer Center), Anita P. Price(Memorial Sloan Kettering Cancer Center)
Cited by 3
Related Papers
Tumour exosome integrins determine organotropic metastasis
|Nature|2015|5.2k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k